Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Current Assets (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Current Assets for 6 consecutive years, with $52.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 39.57% to $52.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $52.4 million, a 39.57% decrease, with the full-year FY2024 number at $74.8 million, up 17.26% from a year prior.
  • Current Assets was $52.4 million for Q3 2025 at Mereo BioPharma, down from $61.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $133.9 million in Q4 2021 to a low of $52.4 million in Q3 2025.
  • A 5-year average of $76.2 million and a median of $70.8 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 241.1% in 2021, then tumbled 43.84% in 2022.
  • Mereo BioPharma's Current Assets stood at $133.9 million in 2021, then crashed by 43.84% to $75.2 million in 2022, then dropped by 15.21% to $63.8 million in 2023, then increased by 17.26% to $74.8 million in 2024, then decreased by 29.9% to $52.4 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Current Assets are $52.4 million (Q3 2025), $61.4 million (Q2 2025), and $66.9 million (Q1 2025).